Immuneering (IMRX) Shares Outstanding (2020 - 2026)

Immuneering's Shares Outstanding history runs 7 years deep, the most recent figure standing at $64.7 million for Q1 2026.

• In Q1 2026, Shares Outstanding rose 79.76% year-over-year to $64.7 million; the TTM figure through Mar 2026 stood at $64.7 million (up 79.76% YoY), while the FY2025 annual figure was $64.6 million, up 108.2% from the prior year.
• Shares Outstanding was $64.7 million for Q1 2026 at Immuneering, roughly flat from $64.6 million in the prior quarter.
• In the past five years, Shares Outstanding ranged from a high of $64.7 million in Q1 2026 to a low of $26.4 million in Q1 2022.
• Historically, Shares Outstanding has averaged $32.2 million across 5 years, with a median of $29.5 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Shares Outstanding gained 0.37% in 2022, then jumped 108.2% in 2025.
• A 5-year view of Shares Outstanding shows it stood at $26.4 million in 2022, then climbed by 10.8% to $29.3 million in 2023, then grew by 6.08% to $31.1 million in 2024, then jumped by 108.2% to $64.6 million in 2025, then increased by 0.06% to $64.7 million in 2026.
• The last three Shares Outstanding figures came in at $64.7 million (Q1 2026), $64.6 million (Q4 2025), and $63.5 million (Q3 2025), per Business Quant data.